Shares of Repligen Corporation (NASDAQ:RGEN) have been given a consensus rating of “Buy” by the seven ratings firms that are presently covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $41.00.
Several equities research analysts have commented on RGEN shares. First Analysis reiterated an “equal weight” rating and issued a $40.00 price target on shares of Repligen Corporation in a research report on Friday, April 21st. BidaskClub cut shares of Repligen Corporation from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, June 14th. Jefferies Group LLC reiterated a “hold” rating and issued a $40.00 price target (up from $33.00) on shares of Repligen Corporation in a research report on Wednesday, June 28th. William Blair started coverage on shares of Repligen Corporation in a research report on Friday, July 21st. They issued an “outperform” rating on the stock. Finally, Zacks Investment Research cut shares of Repligen Corporation from a “buy” rating to a “hold” rating in a research report on Wednesday, July 5th.
A number of hedge funds have recently bought and sold shares of RGEN. Benin Management CORP bought a new stake in Repligen Corporation during the second quarter valued at about $207,000. Macquarie Group Ltd. increased its stake in Repligen Corporation by 481.1% in the fourth quarter. Macquarie Group Ltd. now owns 319,668 shares of the biotechnology company’s stock valued at $9,852,000 after buying an additional 264,659 shares during the last quarter. Karp Capital Management Corp bought a new stake in Repligen Corporation during the first quarter valued at about $506,000. Invictus RG bought a new stake in Repligen Corporation during the first quarter valued at about $233,000. Finally, BNP Paribas Arbitrage SA increased its stake in Repligen Corporation by 13.2% in the first quarter. BNP Paribas Arbitrage SA now owns 6,475 shares of the biotechnology company’s stock valued at $228,000 after buying an additional 753 shares during the last quarter. Hedge funds and other institutional investors own 99.02% of the company’s stock.
Repligen Corporation (NASDAQ:RGEN) traded up 0.59% during trading on Friday, reaching $42.78. 787,082 shares of the company’s stock traded hands. The company has a 50-day moving average of $41.52 and a 200 day moving average of $36.21. Repligen Corporation has a 12 month low of $26.16 and a 12 month high of $46.81. The stock has a market capitalization of $1.46 billion, a P/E ratio of 112.88 and a beta of 1.30.
Repligen Corporation (NASDAQ:RGEN) last issued its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.15 by $0.05. Repligen Corporation had a net margin of 15.61% and a return on equity of 9.90%. The firm had revenue of $32.40 million for the quarter, compared to analysts’ expectations of $31.72 million. During the same period in the previous year, the business earned $0.16 earnings per share. Repligen Corporation’s revenue for the quarter was up 11.0% compared to the same quarter last year. On average, equities research analysts expect that Repligen Corporation will post $0.58 earnings per share for the current fiscal year.
About Repligen Corporation
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
What are top analysts saying about Repligen Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Repligen Corporation and related companies.